This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gatenby, P Articles by O’Neil, R Search for Related Content PubMed PubMed Citation Articles by Gatenby, P Articles by O’Neil, R Social Bookmarking                   What's this?

Antiphospholipid antibodies and stroke in Down syndrome

Department of Immunopathology, The Canberra Hospital and the Canberra Clinical School, University of Sydney, Garran, ACT, Australia, paul.gatenby{at}act.gov.au

R Tuck

Department of Neurology, The Canberra Hospital and the Canberra Clinical School, University of Sydney, Garran, ACT, Australia

C Andrews

Department of Neurology, The Canberra Hospital and the Canberra Clinical School, University of Sydney, Garran, ACT, Australia

R O’Neil

Department of Medical Imaging, The Canberra Hospital and the Canberra Clinical School, University of Sydney, Garran, ACT, Australia

Two patients with Down syndrome and the primary antiphospholipid antibody are described. One patient had a vasculopathy similar to that previously described as Moyamoya. Down syndrome is characterized by immune defects including a tendency to autoimmune phenomena. This report extends the scope of these observations and particularly draws out the potential role of antiphospholipid antibodies. Indeed antiphospholipid antibodies may well explain the well-known association of Down syndrome and stroke.

Key Words: Down syndrome • stroke • antiphospholipid syndrome • Moyamoya

Lupus, Vol. 12, No. 1, 58-62 (2003)
DOI: 10.1191/0961203303lu240cr


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?